iSBTc 22nd Annual Meeting

November 2 - 4, 2007
Seaport World Trade Center
Boston, Massachusetts

22nd Annual Meeting Offers 21 CME Credits

The Annual Meeting has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of the Clinical Immunology Society and the International Society for Biological Therapy of Cancer. The Clinical Immunology Society is accredited by the ACCME to provide continuing medical education for physicians.

The Clinical Immunology Society designates this educational activity for a maximum of 21 AMA PRA Category 1 Credits™. Physicians should claim credit commensurate with the extent of their participation in the activity.

Friday: 8.5 credits    Saturday: 8.0 credits    Sunday: 4.5 credits

Intended Audiences

The target audience for the Annual Meeting incorporates basic and clinical investigators from academic, regulatory, and biopharmaceutical venues. The audience includes clinicians, researchers, students, post-doctoral fellows, and allied health professionals.

Program Purpose/Objectives

  1. Promote scientific dialogue regarding the most recent advances in biological cancer therapy
  2. Facilitate communication and collaborations between laboratory and clinical investigators
  3. Facilitate interactions among scientists in industry, government, and academia regarding cancer research with combination therapies that may lead to better patient outcomes
  4. Discuss regulatory issues that impact cancer clinical trials
  5. Educate students, post-doctoral fellows, and junior faculty in the area of biological therapy and offer opportunities to interact with senior investigators and leaders in the field
  6. Highlight the increasing importance of combination therapies for the treatment of cancer

Expected Outcomes

  1. Attendees will learn about the most recent advances in biologic therapies including cancer vaccines, adoptive T cell therapy, immune regulation, innate immunity and inflammation, angiogenesis, gene therapy, and targeted therapy
  2. Clinical and laboratory investigators will participate in productive collaborations
  3. Members of the pharmaceutical industry and academia will collaborate on the formulation of novel clinical trials, which may lead to better outcomes in cancer patients
  4. Laboratory and clinical investigators will accrue new information with which to pursue fresh initiatives or novel collaborations
  5. Attendees will gain a better understanding of interdisciplinary science and research that can assist in the development of new combinational therapies

Claiming CME

Email correspondence will be sent to all attendees at the conclusion of this program with specific instructions to claim a CME certificate.

Click here to claim your CME credits.